Search

Displaying results 5081 - 5090 of 10000 in total
  1. Drug

    Peldesine

    go.drugbank.com/drugs/DB02568
    Investigational

    Peldesine is a potent inhibitor of human CCRF-CEM T-cell proliferation. It has undergone phase I trials for the treatment of Human Immunodeficiency Virus (HIV) infections.

  2. Drug

    ND7001

    go.drugbank.com/drugs/DB05142
    Experimental

    ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. … Known drug targets of ND7001 including phosphodiesterase 2A, cGMP-stimulated and cGMP-dependent 3',5'-cyclic phosphodiesterase. It is a new type of antidepressant drug with anxiolytic activity.

  3. Drug

    N-(2-Aminoethyl)-1-aziridineethanamine

    go.drugbank.com/drugs/DB15643
    Experimental

    First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease

  4. Drug

    Talizumab

    go.drugbank.com/drugs/DB05797
    Experimental

    TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.

  5. Drug

    Dendritic cells vaccine

    go.drugbank.com/drugs/DB15803
    Investigational

    The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.

  6. Drug

    Amperozide

    go.drugbank.com/drugs/DB08927
    Experimental

    Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication … Amperozide is a diphenylbutylpiperazine atypical antipsychotic which antagonizes 5-HT2A receptors. It inhibits dopamine release and alters the firing of dopaminergic neurons.

  7. Drug

    SR 121463

    go.drugbank.com/drugs/DB05455
    Investigational

    It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH). … SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype.

  8. Drug

    Nicergoline

    go.drugbank.com/drugs/DB00699
    Approved

    An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.

    Categories: Heterocyclic Compounds with 4 or More Rings
  9. Drug

    Sumanirole

    go.drugbank.com/drugs/DB06477
    Investigational

  10. Drug

    Psilocybin

    go.drugbank.com/drugs/DB11664
    Investigational

    Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.